Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal
antibody therapy in treating patients who have metastatic prostate cancer that has not
responded to previous hormone therapy. Drugs used in chemotherapy use different ways to stop
tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as
bevacizumab may stop the growth of cancer cells by stopping blood flow to the tumor.
Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.